Location Directory

Clinical trials in Dallas, Texas

This page shows live ClinicalTrials.gov search results for Dallas, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

13791

Shown on this page

Current sort

Institutions in Dallas

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

UT Southwestern Medical Center

Live official records

Open in full search

Conditions: Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpa, Nr-axSpa
Interventions: Bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 10
States / cities: Glendale, Arizona • Phoenix, Arizona • Upland, California + 7 more

Conditions: Knee Cartilage Defects
Interventions: CARTISTEM® + Debridement, Debridement; Biological · Procedure
Lead sponsor: Medipost, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 37
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 30 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Not listed
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 31 more

Conditions: Neurological Disorder, ALS (Amyotrophic Lateral Sclerosis), Motor Neuron Disease, ALS - Amyotrophic Lateral Sclerosis, ALS
Interventions: Stentrode; Device
Lead sponsor: Synchron, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 5
States / cities: Jacksonville, Florida • Buffalo, New York • New York, New York + 2 more

Conditions: PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer
Interventions: Zovegalisib, Capivasertib, Fulvestrant; Drug
Lead sponsor: Relay Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 52
States / cities: Gilbert, Arizona • Beverly Hills, California • Duarte, California + 42 more

Conditions: Moderate Traumatic Brain Injury (TBI), Severe Traumatic Brain Injury
Interventions: Valproic Acid (VPA), Standard of care treatment + normal saline; Drug · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 9
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 6 more

Conditions: Breast Neoplasms, Neoplasm Metastasis
Interventions: LY4064809, Placebo, Ribociclib, Palbociclib, Abemaciclib, Anastrozole, Letrozole, Exemestane, Fulvestrant; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 132
States / cities: Anchorage, Alaska • Chandler, Arizona • Phoenix, Arizona + 112 more

Conditions: Solid Tumor
Interventions: GS-1206; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Grand Rapids, Michigan • Dallas, Texas • San Antonio, Texas

Conditions: Alcohol Use Disorder
Interventions: LY3537031, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 28
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 23 more

Conditions: Treatment Resistant Depression
Interventions: Vagus Nerve Stimulation (VNS); Device
Lead sponsor: LivaNova; Industry
Eligibility: 18 Years and older
Enrollment: 6,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 101
States / cities: Birmingham, Alabama • Huntsville, Alabama • Burlingame, California + 85 more

Conditions: Kidney Disease
Interventions: Mezagitamab, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 45
States / cities: Birmingham, Alabama • Montgomery, Alabama • Surprise, Arizona + 38 more

Conditions: Asthma
Interventions: FF/UMEC/VI, ELLIPTA, FF/VI; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 28
States / cities: Birmingham, Alabama • Mobile, Alabama • Paradise Valley, Arizona + 23 more

Clinical trials in Dallas, Texas

Filter and sort this location

Institutions in Dallas

Live official records

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis

ASSESS ALL ALS Study

INdependence Through Endovascular Neuroprosthetic Technology (INTENT): an Early Feasibility Study

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Valproic AcId for Traumatic BRAin INjury Trial

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid Tumors

A Study of Brenipatide in Participants With Alcohol Use Disorder

A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma